Jane Skjøth-Rasmussen

Medicine & Life Sciences

1. Glioblastoma 100%
2. Brain Neoplasms 42%
3. Glioma 40%
4. Neoplasms 37%
5. Meningioma 32%
6. ethyl tyrosine ester 23%
7. Child 21%
8. Subarachnoid Hemorrhage 20%
9. Therapeutics 19%
10. Survival 18%
11. Pediatrics 17%
12. Bevacizumab 17%
13. Positron-Emission Tomography 17%
14. Intracranial Vasospasm 16%
15. Urokinase Plasminogen Activator Receptors 16%
16. Intracranial Arteriovenous Malformations 16%
17. Aminolevulinic Acid 16%
18. Recurrence 16%
19. Epilepsy 15%
20. Central Nervous System Neoplasms 14%
21. Tumor Burden 14%
22. Cerebrovascular Circulation 14%
23. Brain 13%
24. Epoprostenol 13%
25. Astrocytoma 13%
26. Mutation 12%
27. Temozolomide 12%
28. Prospective Studies 12%
29. O-(2-fluoroethyl)tyrosine 12%
30. Fluorescence 11%
31. Craniotomy 11%
32. (18F)fluoroethyltyrosine 11%
33. Angiomatoid Fibrous Histiocytoma 10%
34. Medulloblastoma 10%
35. Clofarabine 9%
36. Infratentorial Neoplasms 9%
37. Maintenance 9%
38. Genomic Instability 9%
39. Phosphofructokinase-1 9%
40. Hyperlactatemia 9%
41. Magnetic Resonance Imaging 9%
42. Ependymoma 8%
43. Systematic Reviews 8%
44. Histone Demethylases 8%
45. Histiocytosis 8%
46. Cohort Studies 8%
47. Spinal Cord Neoplasms 8%
48. Population 8%
49. Oxygen 8%
50. Lasers 8%